Visceral and subcutaneous adiposity: Are both potential therapeutic targets for tackling the metabolic syndrome?

Current Pharmaceutical Design

Volumn 13, Issue 21, 2007, Pages 2169-2175

  Rodríguez, Amaia ^a   Catalán, Victoria ^a   Gómez Ambrosi, Javier ^a   Frühbeck, Gema ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; FATTY ACID; INSULIN; INTERLEUKIN 6; LEPTIN; ORAL ANTIDIABETIC AGENT; PHENTOLAMINE; RESISTIN; RETINOL BINDING PROTEIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; VISFATIN; YOHIMBINE;

ADIPOSE TISSUE; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; COMORBIDITY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG TARGETING; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPOLYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

ADIPONECTIN; ADIPOSITY; ANIMALS; CYTOKINES; HUMANS; INSULIN; INTRA-ABDOMINAL FAT; LEPTIN; LIPOLYSIS; METABOLIC SYNDROME X; RETINOL-BINDING PROTEINS; SUBCUTANEOUS FAT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447560040     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781039599     Document Type: Review

References (89)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
2. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998; 47: 699-713.
3. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
4. Kuk JL, Katzmarzyk PT, Nichaman W, Church TS, Blair SN, Ross R. Visceral fat is an independent predictor of all-cause mortality in men. Obesity 2006; 14: 336-41.
5. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-9.
6. Fujioka S, Matsuzawa Y, Tokunaga K, Kawamoto T, Kobatake T, Keno Y, et al. Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity. Int J Obes 1991; 15: 853-9.
7. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci 2003; 24: 276-83.
8. Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, et al. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 1998; 47: 1384-91.
9. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087-94.
10. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 2002; 51: 2951-8.
11. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000; 11: 351-6.
12. Frühbeck G. The adipose tissue as a source of vasoactive factors. Cuff Med Chem Cardiovasc Hematol Agents 2004; 2: 197-208.
13. Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res 2006; 53: 482-91.
14. Unger RH. Lipotoxic diseases. Annu Rev Med 2002; 53: 319-36.
15. Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006; 38: 52-63.
16. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004; 89: 2601-7.
17. Van Harmelen V, Lonnqvist F, Thorne A, Wennhind A, Large V, Reynisdottir S, et al. Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocytes from obese subjects. Int J Obes Relat Metab Disord 1997; 21: 972-9.
18. Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med 1995; 27: 435-8.
19. Arner P. Genetic variance and lipolysis regulation: implications of obesity. Ann Med 2001; 33: 542-6.
20. Degerman E, Landstrom TR, Wijkander J, Holst LS, Ahmad F, Belfrage P, et al. Phosphorylation and activation of hormone-sensitive adipocyte phosphodiesterase 3B. Methods 1998; 14: 43-53.
21. Wijkander J, Landstrom TR, Manganiello V, Belfrage P, Degerman E. Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes, possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase. Endocrinology 1998; 139: 219-27.
22. Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998; 47: 98-103.
23. Zierath JR, Livingston JN, Thorne A, Bolinder J, Reynisdottir S, Lonnqvist F, et al. Regional differences in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia 1998; 41: 1343-54.
24. Wu X, Hoffstedt J, Deeb W, Singh R, Sedkova N, Zilbering A, et al. Depot-specific variation in protein-tyrosine phosphatase activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J Clin Endocrinol Metab 2001; 86: 5973-80.
25. Meek SE, Nair KS, Jensen MD. Insulin regulation of regional free fatty acid metabolism. Diabetes 1999; 48: 10-4.
26. Frühbeck G, Aguado M, Martinez JA. In vitro lipolytic effect of leptin on mouse adipocytes: evidence for a possible autocrine/ paracrine role of leptin. Biochem Biophys Res Commun 1997; 240: 590-4.
27. Frühbeck G, Aguado M, Gómez-Ambrosi J, Martínez JA. Lipolytic effect of in vivo leptin administration on adipocytes of lean and ob/ob mice, but not db/db mice. Biochem Biophys Res Commun 1998; 250: 99-102.
28. Frühbeck G, Gómez-Ambrosi J, Salvador J. Leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes. FASEB J 2001; 15: 333-40.
29. LaNoue KF, Martin LF. Abnormal A1 adenosine receptor function in genetic obesity. FASEB J 1994; 8: 72-80.
30. Frühbeck G, Gómez-Ambrosi J. Depot-specific differences in the lipolytic effect of leptin on isolated white adipocytes. Med Sci Monit 2002; 8: BR47-55.
31. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 2000; 14:1345-51.
32. Sengenes C, Bouloumie A, Hauner H, Berlan M, Busse R, Lafontan M, et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 2003; 278: 48617-26.
33. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.
34. Montague CT, Prins JB, Sanders L, Digby JE, O'Rahilly S. Depot-and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997; 46: 342-7.
35. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
36. Berg AH, Lin Y, Lisanti MP, Scherer PE. Adipocyte differentiation induces dynamic changes in NF-kappaB expression and activity. Am J Physiol Endocrinol Metab 2004; 287: E1178-E88.
37. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000; 11: 212-7.
38. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91: 4854-8.
39. Good M, Newell FM, Haupt LM, Whitehead JP, Hutley LJ, Prins JB. TNF and TNF receptor expression and insulin sensitivity in human omental and subcutaneous adipose tissue - influence of BMI and adipose distribution. Diab Vasc Dis Res 2006; 3: 26-33.
40. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-200.
41. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15: 2792-800.
42. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-49.
43. Esteve E, Villuendas G, Mallolas J, Vendrell J, Lopez-Bermejo A, Rodriguez M, et al. Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clin Endocrinol 2006; 65: 88-91.
44. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-9.
45. Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV. Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455-62.
46. Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998; 47: 913-7.
47. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-7.
48. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-63.
49. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Comm 1999; 257: 79-83.
50. Hotta K, Funahashi T, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, et al. Plasma concentratrion of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscl Thromb Vasc Biol 2000; 20: 1595-9.
51. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules. Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6.
52. Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ, et al. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res 2002; 34: 650-4.
53. Degawa-Yamauchi M, Moss KA, Bovenkerk JE, Shankar SS, Morrison CL, Lelliott CJ, et al. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes Res 2005; 13: 662-9.
54. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9.
55. Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M, Richelsen B. Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity 2006; 14: 28-35.
56. Morinigo R, Musri M, Vidal J, Casamitjana R, Delgado S, Lacy AM, et al. Intra-abdominal fat adiponectin receptors expression and cardiovascular metabolic risk factors in obesity and diabetes. Obes Surg 2006; 16: 745-51.
57. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.
58. Yang RZ, Huang Q, Xu A, McLenithan JC, Eisen JA, Shuldiner AR, et al. Comparative studies of resistin expression and phylo-genomics in human and mouse. Biochem Biophys Res Commun 2003; 310: 927-35.
59. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 997-1001.
60. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5.
61. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003; 149: 331-5.
62. Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004; 89: 1844-8.
63. Gómez-Ambrosi J, Frühbeck G. Evidence for the involvement of resistin on inflammation and cardiovascular disease. Curr Diabetes Rev 2005; 1: 227-34.
64. Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 2006; 91: 2755-60.
65. Reilly MP, Lehrke M, Wolfe ML, Rohatg AL, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-9.
66. Jung HS, Park KH, Cho YM, Chung SS, Cho HJ, Cho SY, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006; 69: 76-85.
67. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83.
68. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-30.
69. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-6.
70. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-9.
71. Quadro L, Blaner WS, Salchow DJ, Vogel S, Piantedosi R, Gouras P, et al. Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. EMBO J 1999; 18: 4633-44.
72. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-62.
73. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-63.
74. Cho YM, Youn BS, Lee H, Min SS, Kwak SH, Lee HK, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006; 29: 2457-61.
75. Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, et al. Retinol-binding protein 4 in human obesity. Diabetes 2006; 55: 2805-10.
76. Frühbeck G. Does a NEAT difference in energy expenditure lead to obesity? Lancet 2005; 366: 615-6.
77. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MF. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21: 457-68.
78. Brook RD, Bard RL, Glazewski L, Kehrer C, Bodary PF, Eitzman DL, et al. Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am J Cardiol 2004; 93: 1012-6.
79. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-72.
80. Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA 2002; 288: 2793-6.
81. Lee WJ, Huang MT, Wang W, Lin CM, Chen TC, Lai IR. Effects of obesity surgery on the metabolic syndrome. Arch Surg 2004; 139: 1088-92.
82. Stich V, de Glisezinski I, Galitzky J, Hejnova J, Crampes F, Riviere D, et al. Endurance training increases the beta-adrenergic lipolytic response in subcutaneous adipose tissue in obese subjects. Int J Obes Relat Metab Disord 1999; 23: 374-81.
83. Hellstrom L, Rossner S, Hagstrom-Toft E, Reynisdottir S. Lipolytic catecholamine resistance linked to alpha 2-adrenoceptor sensitivity - a metabolic predictor of weight loss in obese subjects. Int J Obes Relat Metab Disord 1997; 21: 314-20.
84. Stich V, de Glisezinski I, Crampes F, Suljkovicova H, Galitzky J, Riviere D, et al. Activation of antilipolytic alpha(2)-adrenergic receptors by epinephrine during exercise in human adipose tissue. Am J Physiol 1999; 277: R1076-R83.
85. Gómez-Ambrosi J, Catalán V, Díez-Caballero A, Martínez-Cruz LA, Gil MJ, García-Foncillas J, et al. Gene expression profile of omental adipose tissue in human obesity. FASEB J 2004; 18: 215-7.
86. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 2002; 87: 5662-7.
87. Botham KM, Bravo E, Elliott J, Wheeler-Jones CP. Direct interaction of dietary lipids carried in chylomicron remnants with cells of the artery wall: implications for atherosclerosis development. Curr Pharm Des 2005; 11(28): 3681-95.
88. Jaumdally JR, Lip GY, Varma C. Traditional risk factors for coronary atherosclerosis in Indo Asians: the need for a reappraisal. Curr Pharm Des 2006; 12(13): 1611-21.
89. Wannamethee SG. Serum uric acid and risk of coronary heart disease. Curr Pharm Des 2005; 11(32): 4125-32.